|
REPL | Replimune Group, Inc. |
|
|
REPL | Replimune Group, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.48 |
| Leverage | 32.38% |
| Market Cap | $ 553.1m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -309.0m |
| Margin | 10515.02% |
Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.